Key Findings
The University of California San Diego (UCSD) is at the forefront of accelerating innovative cell therapy development for advanced solid tumors, actively progressing multiple Phase 1 clinical trials. These studies are specifically focused on novel “off-the-shelf” and logic-gated allogeneic CAR-T cells, as well as gamma delta T-cell therapies, designed to overcome the inherent challenges faced by existing CAR-T cell approaches in solid tumor indications.
Technical / Clinical Details
Key Phase 1 trials currently underway at UCSD include:
- **FT825/ONO-8250**: This is an off-the-shelf CAR-T cell therapy targeting HER2, intended for patients with advanced solid tumors. Off-the-shelf therapies eliminate the need for patient-specific customization, streamlining manufacturing, reducing costs, and improving accessibility for a broader patient population. While HER2 is overexpressed in many cancers, uniform targeting remains a challenge.
- **A2B395**: An allogeneic (donor-derived) logic-gated CAR T-cell product, specifically engineered to activate only within a defined tumor microenvironment. This design aims to enhance tumor-specific killing while minimizing off-target toxicities. Logic gates activate cells only when multiple conditions are met, thereby improving the safety profile.
- **ACE2016**: An off-the-shelf, allogeneic gamma delta T (γδT) cell therapy targeting EGFR (epidermal growth factor receptor)-expressing solid tumors. Unlike conventional alpha-beta T-cells, γδT cells possess unique properties, including MHC-independent tumor recognition, making them promising candidates for anti-tumor activity within the complex solid tumor microenvironment.
These trials primarily assess the safety and tolerability of these novel therapies in patients with refractory advanced solid tumors, with preliminary efficacy also being monitored.
Background & Context
While CAR-T cell therapy has revolutionized hematological cancer treatment, its impact on solid tumors has been limited. This is attributed to challenges such as the scarcity of uniformly expressed target antigens, the immunosuppressive nature of the tumor microenvironment, and limitations in CAR-T cell infiltration into tumors. To address these issues, the industry is actively developing next-generation approaches. These include the creation of “off-the-shelf” products for rapid, widespread patient access and the incorporation of logic-gated CARs to enhance tumor specificity and reduce off-target toxicity. Furthermore, research into leveraging unconventional T-cell repertoires, such as γδT cells, is advancing, aiming to open new frontiers in immunotherapy for solid tumors.
Strategic Significance & Outlook
The clinical trials being advanced at UCSD represent a crucial step towards providing new therapeutic options for patients with advanced solid tumors. The focus on “off-the-shelf” products, logic-gated allogeneic CAR-T, and γδT cell therapies signifies the direction of next-generation cell therapies in terms of manufacturing simplification, reduced treatment costs, and improved safety and efficacy. Should these technologies prove successful, they hold the potential to significantly improve patient prognoses in many intractable solid tumors and substantially broaden the applicability of cell therapies. The data emerging from these Phase 1 trials will be instrumental in guiding further development decisions and the design of future, larger-scale clinical studies.
Source: https://clinicaltrials.ucsd.edu/solid-tumor
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments